The median survival time was 1.82 years (95% CI -1.57; 2.06). A univariable analysis was performed for SUV descriptors and metabolic features. Results for the statistically significant metabolic features (p-value<0.05) are shown in Table 1 . AVAI of 0.5 and 1, and AVRI of 10% showed a high correlation (Pearson correlation = 0.999,0.992 and 0.995) with GTV. Both RVRI of 80% and 90% (Pearson correlation =0.888) revealed a good prognostic value, outperforming the SUV descriptors.
Purpose/Objective: SBRT for early stage non-small cell lung cancer is increasingly applied by many centres. Therefore, FDG-PET/CT is widely accepted as mandatory pre-treatment staging procedure, however, its timing is not standardised. In patients with locally advanced NSCLC, a high rate of tumou rgrowth and disease progression has been demonstrated when repeating the FDG-PET/CT during the SBRT planning phase accounting to about 30% upstaging probability within three weeks. The aim of this study was to investigate the FDG-PET/CT progression rate prior to SBRT. Materials and Methods: Nineteen consecutive early stage NSCLC patients referred for SBRT to the University Hospital Freiburg between 08/2008 and 08/2011 were retrospectively analysed. All patients had already undergone an FDG-PET/CT scan at the time of referral and underwent a second FDG PET/CT for radiation planning purposes. All scans were analysed by two investigators blinded for treatment outcome regarding: availability of scan, tumour size and thus clinical T-stage, maximum standardized uptake value (SUV max ) in the tumour, additional FDG uptake in hilar/mediastinal lymph nodes (cN1/2) or at distant sites (cM1a/b). Progressive disease (>25% increase of tumour diameter on CT or >25% increase in SUV max ) and the time-interval between both imaging modalities were related to overall survival. Results: Median time interval between the diagnostic and planning FDG-PET/CT scan was 43 days (range: 22-140 days). After the planning FDG-PET/CT, 3/19 (15.8%) patients were not amenable for SBRT anymore due to diagnosis of nodal metastases (interscan interval: 22, 51, and 95 days, respectively). No patients were found to have distant metastases. In the remaining 16 patients, no additional lesions were found, but one patient had progression in tumour diameter and two in SUV max values. Notwithstanding, the lesions were still eligible for SBRT. Overall, upstaging occurred in 6/19 (31.6%) of patients, all but one with an interscan interval of more than 43 days (average 60 days, range 22-95 days). Overall, the upstaging probability with an interscan interval of less than 3 weeks was 0%. Furthermore, an SUV max above median (9.50) on the diagnostic FDG-PET/CT scan was of borderline significance(p=0.06) for overall survival. Conclusions: In patients scheduled for SBRT, the rate of tumour growth and disease progression seen by repeated FDG-PET/CT was lower as compared to the situation in locally advanced disease. However, due to the risk of undertreatment of nodal progression in 15.8% of cases, a timely scheduling of pre-treatment staging FDG-PET/CT is recommended.
SYMPOSIUM: IMAGE-BASED ASSESSMENT OF THE RESPONSE OF NORMAL TISSUES TO RT
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Radiation therapy (RT) is a major treatment modality for brain tumors. As combining radiation therapy with chemotherapy and molecular targeted therapy is improving survival, neurotoxicity, including cognitive function decline and normal tissue necrosis, becomes an issue of quality of life. Clinical symptoms and cognitive decline usually occur delayed or late as weeks, months or even years after the completion of RT. The clinical outcome ranges from mild, reversible damage to irreversible injury. In the past, efforts to develop models to estimate the likelihood of developing radiationinduced neurotoxicity have been primarily based on the planned radiation dose distribution, dose fraction size, and dose volume. These analyses have demonstrated their usefulness for permitting the safe delivery of higher doses of radiation than have previously been possible. However, there is a broad range of individual patient sensitivity that is not reflected by predictions made solely based on the physical dose distribution or general clinical features. If individual patient response to radiation could be better estimated before or during a course of treatment, it would permit higher doses of radiation to be delivered safely to the tumors of patients who is relatively radiation resistant, thus prolonging survival without increasing complications.
It would be valuable to identify biomarkers, including those derived from in vivo imaging, for early assessment of individual sensitivity to radiation and prediction of delayed and late neurotoxicity. Such biomarkers might provide an opportunity to individualize the dose of RT. Our group has been conducting active research in this area. We have used diffusion tensor (DTI) and dynamic contrast enhanced (DCE) MRI to assess individual and brain structural sensitivity to radiation. Structural-variation in sensitivity to radiation may be related to the selective cognitive decline after brain irradiation. Our results indicate that combining the early changes in the DTI and DCE indices of brain functional structures with doses has the potential to improve the prediction of delayed or late cognitive decline and/or brain tissue necrosis.
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Heart irradiation and comorbidity correlates with lung toxicity after (chemo)radiotherapy G. Nalbantov 1 , B. Kietselaer 2 , C. Oberije 3 , E. Troost 3 , A. Dekker 3 , P. Radiation-induced lung toxicity (RILT) is one of the main dose-limiting factors in lung cancer treatment. It usually occurs within 3-6 months after the start of (chemo)radiotherapy and manifests itself with dyspnea, cough and fever. While the delivered dose to the lung is the primary cause of lung damage, different patients exhibit different susceptibility. In fact, only about 15%-25% of all lung cancer patients develop serious dyspnea problems (grade >=2 according to the Common Toxicity Criteria (CTC)), despite receiving a similar mean lung dose (15-20 Gy) as the rest of patients. It is therefore likely that other determinants, including clinical, dosimetric and tumor-related features, contribute to the observed individual susceptibility to lung damage. Since the heart and the lung form the interrelated cardiopulmonary system, we hypothesize that the radiation dose delivered to the heart is likely to be an important contributor to the development of dyspnea, especially so in patients with cardiac comorbidity. Interestingly, while it has been shown that radiation to the heart increases the long-term risk of a cardiac event, insufficient research has been carried out on the short-term (3-6 months) effects of cardiac comorbidity and heart irradiation on the risk of radiotherapy-induced lung damage. Does the heart matter for RILT? Are there specific cardiac comorbidities associated with a higher probability of lung damage? Is there a short-term pulmonary effect from (excessive) heart irradiation? These research questions will be addressed in the talk, and recent promising evidence on this topic will be discussed. Compared to 3D conformal radiotherapy (3DCRT), the advent of intensity modulated Radiotherapy (IMRT) for head andneck cancer patients (HNC) gave the possibility to dramatically reduce the dose to non-involved structures, and this is reported to be correlated to a reduced toxicity suffered by the patient. Nevertheless, even with IMRT, different toxicities continue to affect the quality of life of HNC patients after RT, being xerostomia and dysphagia two of the most important. In this context, it could be of particular interest the assessment of parameters able to predict individual patient tissue reactions during the treatment and possibly the risk of developingacute and/or late toxicity. This information could be used in order to select patients that may gain advantages by the implementation of personalized adaptive treatments and/or supportive therapies with the aim of reducing toxicity. Structural and volume variations of tissues/organs may be a sign of a radiation induced damage and could be measured using different image modalities. Image guided RT (IGRT) itself represents a powerful database of computed tomography (CT) images acquired during the treatment course, that in principle could be used to derive information regarding the tissues and organs reaction; also diagnostic CTs collected during the treatment for adaptive re-planning are another important source of available, high-quality CT information. Organs at risk (OAR) in HN region, such as parotid glands (PGs) or constrictor muscles, are known to undergo large volume and shape changes during RT treatments (that can be easily detected by CTimages acquired during IGRT), and this is reported to be related to organ dysfunction. For example, PGs are known to shrink during HN treatment. In literature it is reported that the volume reduction at the end of therapy of 30-35 fractions/45 days is around 30-35%. On the other hand, density variation of organs during the treatment course may be considered as a surrogate of changes in tissue structure and therefore a potential measure of a radiation induced functional damage. Based on CT-images, it is possible to directly measure density variations in terms of Hounsfield units (HU) difference between images acquired during the treatment course. Focusing on PGs, recent hystopathological studies of tissue samples showed a reduction of the acinar cells number, with a relative increase of fat component in irradiated PGs compared to not irradiated, and this data is likely to be measured by CT-based density variation. Consistently, PGs density variation was found to vary significantly during the RT course in a large population of patients treated with IMRT; the largest variation was found during the first half part of the treatment compared to end (p-value=0.0001). Moreover, the early PGs density/volume variations, i.e.during the first two weeks of treatment, were found to be good predictors of the final changes at the end of the therapy (AUC>0.75, p-value=0.0001). Importantly, the median early PGs density variation resulted to be significantly different for a group of 25 patients with a prospectively assessed acute xerostomia score (CTC v3.0) during the treatment course. CT-based biomarkers assessed during the RT treatment course, such as volume, density and texture parameters, should be considered as promising scores which are likely to be surrogates of organ damage and consequently related to the probability risk to develop acute and/or late toxicity.
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